• zh-hans
  • en
Loading...
News 2017-08-27T11:42:49+00:00

15 August 2017

Vascular Dynamics Announces FDA Approval to Initiate
CALM 2 Trial for MobiusHD® System

Vascular Dynamics, Inc., a privately held medical device company developing novel solutions for the treatment of hypertension, today announces that the United States Food and Drug Administration (FDA) has approved the company’s Investigational Device Exemption (IDE) application to initiate its pivotal trial for its MobiusHD® System for the treatment of resistant hypertension.

MORE
更多

27 April 2017

Vascular Dynamics is Featured on ISRAEL21c

Vascular Dynamics, and its MobiusHD device for treatment of resistant hypertension, are featured on the ISRAEL21c online magazine. The article describes the company, technology and clinical trials results which to date have shown that upon discharge, MobiusHD patients’ clinical blood pressure is down about 36 points.

MORE

15 February 2017

GluSense Receives Investment from JDRF T1D Fund

GluSense Ltd., a medical device company developing a long lasting injectable glucose sensor for treatment of Type 1 Diabetes (T1D), today announced it has received an investment from the JDRF T1D Fund, a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial programs.

MORE

1 February 2017

Vascular Dynamics’ Announces Expedited Access Pathway Designation by FDA for MobiusHD® to Accelerate US Access for Treatment of Resistant Hypertension

­Vascular Dynamics, Inc., is a privately held medical device company developing novel solutions for the treatment of hypertension, today announces that the United States Food and Drug Administration (FDA) has approved the company’s application to participate in the Expedited Access Pathway (EAP) program for its MobiusHD ® device for the treatment of resistant hypertension.

MORE

7 September 2016

BlueWind Medical Announces CE-Mark for the BlueWind VIVENDI™ miniature implanted wireless stimulator to treat Peripheral Pain

Bluewind Medical, developer of a miniature wireless neurostimulation platform to treat multiple clinical indications, announced today that the company has received CE-Mark for the BlueWind’s VIVENDI miniature wireless neurostimulator to treat Peripheral Neuropathic Pain (PNP).

 

MORE

15 June 2016

BlueWind Medical Announces CE-Mark for BlueWind RENOVA™, the first in the world miniature wireless neurostimulator to treat Overactive Bladder

Bluewind Medical, developer of a miniature wireless neurostimulation platform to treat multiple clinical indications, announced today that the company has received CE-Mark for its BlueWind RENOVA System, the first in the world miniature wireless neurostimulator to treat Overactive Bladder (OAB).

 

MORE

3 June 2016

Vascular Dynamics Appoints James T. McKinley as Chief Operating Officer

Vascular Dynamics, Inc., a privately held medical device company developing novel solutions for the treatment of hypertension, today announced the appointment of James T. McKinley as Chief Operating Officer.

MORE

3 Mar 2016

Rainbow Medical to Collaborate With Johnson & Johnson Innovation

Rainbow Medical, a company owned by Leon Recanati, Efi Cohen-Arazi and Yossi Gross, is dedicated to the development of medical device companies. Today they announced a collaboration with Medos International Sarl, part of the DePuy Synthes Companies of Johnson & Johnson. This deal was facilitated by Johnson & Johnson Innovation. The collaboration will be focused on the development of a novel therapy for treating spinal degenerative disc disease.

MORE

11 January 2016

BlueWind Medical Announces Successful Completion of Patients’ Enrolment for Its Overactive Bladder (OAB) Clinical Study Toward a CE Mark

Bluewind Medical, developer of a wireless neuro-stimulation device to treat multiple clinical indications, such as back pain, peripheral neuropathic pain, incontinence (OAB), epilepsy, and more, announced today the completion of patient enrolment for an Overactive Bladder (OAB) study which is currently being conducted to support CE Mark submission.

MORE

6 January 2016

MobiusHD™ System Receives CE Mark for the Treatment of Resistant Hypertension

Vascular Dynamics, Inc., a private medical device company developing novel solutions for the treatment of hypertension, today announced receipt of CE Mark approval for its MobiusHD™ System, a minimally invasive system for the treatment of resistant hypertension.

MORE

22 FEB 2015

Rainbow Medical raises $25m from Chinese investors
The medical device start-up investor has set up a China office for strategic collaborations. Rainbow Medical, which specializes in seed and incubator investments in medical device start-ups and developing breakthrough medical technologies, has raised $25 million from investors in China. Rainbow Medical has also opened a China office to promote strategic collaborations

MORE

5 Nov 2015

BlueWind Medical Announces Successful Completion of Patients’ Follow-Up for Its Peripheral Neuropathic Pain (PNP) Study Toward a CE Mark

Bluewind Medical, developer of the a wireless neurostimulation device to treat multiple clinical indications, such as pain management, incontinence (OAB), epilepsy, sleep-apnea and more, announced today the completion of patient follow up for a peripheral neuropathic pain (PNP) study for its CE submission.

 

MORE

5 Nov 2015

World’s First Endovascular Neuromodulation Device Implanted in Man for the Treatment of Congestive Heart Failure

Enopace Biomedical, a developer of minimally invasive, implantable endovascular neuromodulation therapy for heart failure patients, announced today the first successful human implantation of its HarmonyTM System, a catheter-based neurostimulator device to treat patients with congestive heart failure.

MORE